Cinclus Pharma Holding AB (publ)
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more
Cinclus Pharma Holding AB (publ) (J8P) - Total Assets
Latest total assets as of September 2025: €587.90 Million EUR
Based on the latest financial reports, Cinclus Pharma Holding AB (publ) (J8P) holds total assets worth €587.90 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cinclus Pharma Holding AB (publ) - Total Assets Trend (2021–2024)
This chart illustrates how Cinclus Pharma Holding AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cinclus Pharma Holding AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Cinclus Pharma Holding AB (publ)'s total assets of €587.90 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 94.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Cinclus Pharma Holding AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cinclus Pharma Holding AB (publ)'s current assets represent 99.9% of total assets in 2024, an increase from 98.8% in 2021.
- Cash Position: Cash and equivalents constituted 94.3% of total assets in 2024, up from 93.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Cinclus Pharma Holding AB (publ) Competitors by Total Assets
Key competitors of Cinclus Pharma Holding AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Cinclus Pharma Holding AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cinclus Pharma Holding AB (publ) generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cinclus Pharma Holding AB (publ) is currently not profitable relative to its asset base.
Cinclus Pharma Holding AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.08 | 14.80 | 14.80 |
| Quick Ratio | 6.08 | 14.80 | 14.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €482.44 Million | € 612.46 Million | € 612.46 Million |
Cinclus Pharma Holding AB (publ) - Advanced Valuation Insights
This section examines the relationship between Cinclus Pharma Holding AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 536.6% |
| Total Assets | €601.01 Million |
| Market Capitalization | $48.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cinclus Pharma Holding AB (publ)'s assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cinclus Pharma Holding AB (publ)'s assets grew by 536.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cinclus Pharma Holding AB (publ) (2021–2024)
The table below shows the annual total assets of Cinclus Pharma Holding AB (publ) from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €601.01 Million | +536.58% |
| 2023-12-31 | €94.41 Million | -49.18% |
| 2022-12-31 | €185.77 Million | +26.22% |
| 2021-12-31 | €147.18 Million | -- |